Risankizumab Provides Durable Quality of Life Improvements out to 100 Weeks in Psoriatic Arthritis

An analysis of 100 week data from the KEEPsAKE 1 and 2 trials presented at EULAR 2023 offers insight into the long-term effects of risankizumab use in people with psoriatic arthritis.

Related Keywords

Italy ,Milan ,Lombardia ,Lars Erik Kristensen ,Eli Lilly ,Amgen ,Parker Institute ,European Congress ,Pfizer ,Novartis ,Bristol Myers Squibb ,European Congress On Rheumatology ,Ann Rheum ,